Fed Study of Olmesartan Medoxomil and Hydrochlorothiazide Tablets 40 mg/25 mg and Benicar HCT® Tablets 40 mg/25 mg
Status:
Completed
Trial end date:
2006-11-01
Target enrollment:
Participant gender:
Summary
The objective of this study was to investigate the bioequivalence of Mylan's olmesartan
medoxomil and hydrochlorothiazide 40 mg/25 mg tablets to Sankyo's Benicar HCT® 40 mg/25 mg
tablets following a single, oral 40 mg/25 mg (1 x 40 mg/25 mg) dose administered under fed
conditions.